Shopping Cart

No products in the cart.

SERUM

Associations of Serum Lipid Traits With Fracture and Osteoporosis: A Prospective Cohort Study From the UK Biobank.

Previous studies reveal inconsistent associations between serum lipid traits and the risks of fractures and osteoporosis in the general population. This prospective cohort study analysed data from 414โ€‰302 UK Biobank participants (223โ€‰060 women and 191โ€‰242 men, aged 37-73โ€‰years) with serum...
๐Ÿ—“๏ธ 2024-10-29
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAssociations of Serum Lipid Traits With Fracture and Osteoporosis: A Prospective Cohort Study From the UK Biobank.

Adenosine A2B receptor activation regulates the balance between T helper 17 cells and regulatory T cells, and inhibits regulatory T cells exhaustion in experimental autoimmune myositis.

Idiopathic inflammatory myopathy (IIM) is a systemic autoimmune disease characterized by skeletal muscle involvement. This study aimed to investigate the role of adenosine receptor signalling pathways in the development of experimental autoimmune myositis (EAM). An ecto-5'-nucleotidase (CD73) inhibitor, adenosine receptor...
๐Ÿ—“๏ธ 2024-09-16
๐Ÿ“ฐ Publication: Journal Of Cachexia Sarcopenia And Muscle
Read MoreAdenosine A2B receptor activation regulates the balance between T helper 17 cells and regulatory T cells, and inhibits regulatory T cells exhaustion in experimental autoimmune myositis.

Ponsegromab for the Treatment of Cancer Cachexia.

Cachexia is a common complication of cancer and is associated with an increased risk of death. The level of growth differentiation factor 15 (GDF-15), a circulating cytokine, is elevated in cancer cachexia. In a small, open-label, phase 1b study involving...
๐Ÿ—“๏ธ 2024-09-14
๐Ÿ“ฐ Publication: New England Journal Of Medicine
Read MorePonsegromab for the Treatment of Cancer Cachexia.

Identification of a novel biomarker for sarcopenia diagnosis using serum metabolomic analysis: a pilot study.

This pilot study compared serum metabolites in participants with and without sarcopenia. Metabolomic techniques were applied to identify serum metabolites and novel biomarkers specific to patients with sarcopenia. In accordance with AWGS2019 criteria, sarcopenia was defined as low muscle mass...
๐Ÿ—“๏ธ 2024-01-12
๐Ÿ“ฐ Publication: European Geriatric Medicine
Read MoreIdentification of a novel biomarker for sarcopenia diagnosis using serum metabolomic analysis: a pilot study.

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!